66 related articles for article (PubMed ID: 7912926)
1. Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185.
Miller P; Schnur RC; Barbacci E; Moyer MP; Moyer JD
Biochem Biophys Res Commun; 1994 Jun; 201(3):1313-9. PubMed ID: 7912926
[TBL] [Abstract][Full Text] [Related]
2. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.
Miller P; DiOrio C; Moyer M; Schnur RC; Bruskin A; Cullen W; Moyer JD
Cancer Res; 1994 May; 54(10):2724-30. PubMed ID: 7909494
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.
Schnur RC; Corman ML; Gallaschun RJ; Cooper BA; Dee MF; Doty JL; Muzzi ML; Moyer JD; DiOrio CI; Barbacci EG
J Med Chem; 1995 Sep; 38(19):3806-12. PubMed ID: 7562911
[TBL] [Abstract][Full Text] [Related]
4. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
5. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships.
Schnur RC; Corman ML; Gallaschun RJ; Cooper BA; Dee MF; Doty JL; Muzzi ML; DiOrio CI; Barbacci EG; Miller PE
J Med Chem; 1995 Sep; 38(19):3813-20. PubMed ID: 7562912
[TBL] [Abstract][Full Text] [Related]
6. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases.
Sakagami M; Morrison P; Welch WJ
Cell Stress Chaperones; 1999 Mar; 4(1):19-28. PubMed ID: 10467105
[TBL] [Abstract][Full Text] [Related]
7. Induction of heat shock proteins by tyrosine kinase inhibitors in rat cardiomyocytes and myogenic cells confers protection against simulated ischemia.
Conde AG; Lau SS; Dillmann WH; Mestril R
J Mol Cell Cardiol; 1997 Jul; 29(7):1927-38. PubMed ID: 9236146
[TBL] [Abstract][Full Text] [Related]
8. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
9. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
10. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition.
Whitesell L; Shifrin SD; Schwab G; Neckers LM
Cancer Res; 1992 Apr; 52(7):1721-8. PubMed ID: 1551101
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
12. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Bonvini P; An WG; Rosolen A; Nguyen P; Trepel J; Garcia de Herreros A; Dunach M; Neckers LM
Cancer Res; 2001 Feb; 61(4):1671-7. PubMed ID: 11245482
[TBL] [Abstract][Full Text] [Related]
13. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.
Chavany C; Mimnaugh E; Miller P; Bitton R; Nguyen P; Trepel J; Whitesell L; Schnur R; Moyer J; Neckers L
J Biol Chem; 1996 Mar; 271(9):4974-7. PubMed ID: 8617772
[TBL] [Abstract][Full Text] [Related]
14. [Protein kinase inhibitors--screening of new molecular target therapeutics].
Uehara Y
Gan To Kagaku Ryoho; 1997 Jan; 24(2):136-44. PubMed ID: 9030224
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway.
Yen L; Nie ZR; You XL; Richard S; Langton-Webster BC; Alaoui-Jamali MA
Oncogene; 1997 Apr; 14(15):1827-35. PubMed ID: 9150389
[TBL] [Abstract][Full Text] [Related]
16. [Anticancer agents targeting oncogene products].
Uehara Y
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1885-91. PubMed ID: 8379683
[TBL] [Abstract][Full Text] [Related]
17. Herbimycin A inhibits angiogenic activity in endothelial cells and reduces neovascularization in a rat model of retinopathy of prematurity.
McCollum GW; Rajaratnam VS; Bullard LE; Yang R; Penn JS
Exp Eye Res; 2004 May; 78(5):987-95. PubMed ID: 15051479
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.
Whitesell L; Mimnaugh EG; De Costa B; Myers CE; Neckers LM
Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8324-8. PubMed ID: 8078881
[TBL] [Abstract][Full Text] [Related]
19. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
[TBL] [Abstract][Full Text] [Related]
20. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.
Hartmann F; Horak EM; Cho C; Lupu R; Bolen JB; Stetler-Stevenson MA; Pfreundschuh M; Waldmann TA; Horak ID
Int J Cancer; 1997 Jan; 70(2):221-9. PubMed ID: 9009164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
